TrialCancer chemotherapy and pharmacology2019

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Whitney P Kirschbrown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.